Industry & Business

Construction to start on GCP2 Production Facility at Takeda Ireland Ltd site

 Breaking News
  • Cyber attack hits IT systems in Ireland and UK Several organisations including big business and government offices in eastern Europe have been hit by a worldwide cyber attack. It has been reported that companies in Ireland may also have been affected, with computer systems at shipping group Maersk failing across regions including Ireland. Danish, British and Spanish multinationals have also been hit by the [...]...
  • Irish and UK retailers highlight Brexit challenges Retail Ireland, the Ibec group that represents the sector, has joined forces with the British Retail Consortium and the Northern Ireland Retail Consortium to explore the implications for the sector arising from Brexit. They will meet in Dublin with a number of Government Departments, consumer advocates and individual retailers to seek solutions to mitigate the [...]...
  • Best ever month of May for Irish tourism Commenting on figures published today by the CSO for overseas visitors to Ireland for January to May, Niall Gibbons, CEO of Tourism Ireland, said: “I am pleased to see growth of more than +3% for the five-month period January-May, coming on the back of a record performance in 2016 and years of solid growth in [...]...
  • New CEO at Barclays Bank Ireland Barclays Bank Ireland has announced the appointment of Kevin Wall as its new chief executive. He succeeds Sarah Wiggins who will take up a new role within Barclays as head of east and south east in UK corporate banking next month. Mr Wall joined Barclays in 1981 and has held a variety of roles across the business, [...]...
  • €330,000 funding announced for ‘Women’s Rural Entrepreneurial Network’ New funding has been announced for female entrepreneurs living in Cork and Limerick. The Women’s Rural Entrepreneurial Network (WREN) project will see more than €330,000 in funding, provided by the Department of Justice and Equality and the European Social Fund, allocated to promote entrepreneurial skills amongst women in these regions, through a tailored and focused [...]...

Construction to start on GCP2 Production Facility at Takeda Ireland Ltd site

Construction to start on GCP2 Production Facility at Takeda Ireland Ltd site
June 01
09:00 2017

Takeda Pharmaceutical Company Limited has announced that a groundbreaking ceremony has been held for its new production facility at the existing Grange Castle site in Ireland. Takeda’s existing footprint at the Grange Castle site will be expanded with the construction of a new standalone, high-containment production facility dedicated to manufacturing its oncology product NINLARO for global markets. The investment will create approximately 40 new jobs over the next two years.

“Our new plant in Grange Castle, Ireland is a strategic investment for Takeda,” said Thomas Wozniewski, Head of Global Manufacturing & Supply. “It will give us the crucial in-house manufacturing capacity to meet the increasing demand for our innovative product NINLARO.”

The construction of the plant, which begins in June 2017, will be managed by Project Management Group with over €40 million investment in total. The plant is scheduled to be completed in Q2 FY18 and become operational to commence shipment of secondary packaged product in the second half of FY18.

The new production facility will be unique in that it will house the Drug Substance, Drug Product, Primary and Secondary Packaging and QC processes all under one roof.

NINLARO was approved in November 2015 by the U.S. Food and Drug Administration (FDA). It is the first and only once-weekly oral proteasome inhibitor launched in the U.S. for the treatment of patients with multiple myeloma who have received at least one prior therapy, enabling an all-oral proteasome inhibitor-based triplet treatment regimen for the first time. Additionally, NINLARO® was approved by the Japanese Ministry of Health, Labour and Welfare in March 2017 and launched in May as the first oral proteasome inhibitor in Japan, indicated in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma.

About Author

editor

editor

Related Articles






Advertisements

































National Manufacturing Conference & Exhibition 2016

NIBRT Springboard Success Stories



Upcoming Events

  • No upcoming events
AEC v1.0.4

Join our Newsletter!



By subscribing you agree to receive updates from us by email. You can opt out of receiving emails at any time.